Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $720M | $212M | $98M | $119M | 12.4% | -1.7% | -38.5% |
| 2024 | $732M | $277M | $160M | $172M | 21.8% | 13.6% | 16.0% |
| 2023 | $644M | $240M | $138M | $145M | 21.5% | 29.1% | 50.5% |
| 2022 | $499M | $146M | $91M | $65M | 17.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 498.99 | 644.40 | 731.97 | 719.89 |
| Operating Revenue | - | 498.99 | 593.24 | 712.81 | 719.89 |
| Cost Of Revenue | - | 250.13 | 293.27 | 358.11 | 363.83 |
| Gross Profit | - | 248.86 | 351.12 | 373.86 | 356.06 |
| Operating Expense | - | 141.36 | 154.13 | 168.44 | 215.65 |
| Research And Development | - | 74.77 | 73.74 | 73.91 | 85.84 |
| Selling General And Administration | - | 66.59 | 80.39 | 94.52 | 129.81 |
| Total Expenses | - | 391.49 | 447.41 | 526.55 | 579.48 |
| Operating Income | - | 107.50 | 196.99 | 205.42 | 140.40 |
| Total Operating Income As Reported | - | 107.50 | 196.99 | 205.42 | 140.40 |
| EBITDA | - | 146.16 | 240.29 | 277.31 | 212.31 |
| Normalized EBITDA | - | 146.16 | 240.29 | 277.31 | 212.31 |
| EBIT | - | 117.89 | 198.52 | 220.11 | 149.10 |
| Interest Income | - | 1.32 | 5.46 | 10.61 | 8.68 |
| Interest Expense | - | 1.85 | 27.16 | 30.34 | 25.48 |
| Net Interest Income | - | -0.52 | -21.70 | -19.73 | -16.80 |
| Other Non Operating Income Expenses | - | 9.07 | -3.93 | 4.08 | 0.02 |
| Other Income Expense | - | 9.07 | -3.93 | 4.08 | 0.02 |
| Interest Income Non Operating | - | 1.32 | 5.46 | 10.61 | 8.68 |
| Interest Expense Non Operating | - | 1.85 | 27.16 | 30.34 | 25.48 |
| Net Non Operating Interest Income Expense | - | -0.52 | -21.70 | -19.73 | -16.80 |
| Pretax Income | - | 116.04 | 171.36 | 189.76 | 123.62 |
| Tax Provision | - | 23.48 | 31.83 | 29.67 | 25.53 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Net Income From Continuing And Discontinued Operation | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Net Income From Continuing Operation Net Minority Interest | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Net Income | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Net Income Common Stockholders | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Net Income Including Noncontrolling Interests | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Normalized Income | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Diluted NI Availto Com Stockholders | - | 91.39 | 137.54 | 159.52 | 98.09 |
| Basic Average Shares | - | 48.55 | 48.26 | 48.43 | 46.74 |
| Diluted Average Shares | - | 52.43 | 53 | 52.06 | 48.22 |
| Reconciled Depreciation | - | 28.28 | 41.78 | 57.20 | 63.20 |
| Reconciled Cost Of Revenue | - | 250.13 | 293.27 | 358.11 | 363.83 |
| Minority Interests | -1.18 | 0 | 0 | - | - |
| Earnings From Equity Interest Net Of Tax | - | -1.18 | -1.98 | -0.57 | 0 |
| General And Administrative Expense | - | 45.06 | 51.54 | 56.72 | 85.92 |
| Other Gand A | - | 45.06 | 51.54 | 56.72 | 85.92 |
| Selling And Marketing Expense | - | 21.53 | 28.85 | 37.80 | 43.88 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc.this co. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Theravance Biopharma, Inc. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| Janux Therapeutics, Inc. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| LB Pharmaceuticals Inc | LBRX |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $829M |
| -32.88 |
| 2.75 |
| -8.4% |
| -19.35 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Peer Median | - | -6.41 | 2.16 | -10.1% | -3.81 | |
Historically, Mar has averaged the highest return (+8.1%); Sep the lowest (-7.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.1%Neutral MonthJan 2026: -1.08% | -23.6%Negative MonthFeb 2026: -23.63% | -3.2%Negative MonthMar 2026: -3.16% | +12.1%Positive MonthApr 2026: +12.10% | -14.2%Negative MonthMay 2026: -14.16% | +7.1%Positive MonthJun 2026: +7.06% | -1.2%Neutral MonthJul 2026: -1.19% | +9.0%*Positive MonthAug 2026: +9.03% | — | — | — | — |
| 2025 | -6.1%Negative MonthJan 2025: -6.09% | -18.5%Negative MonthFeb 2025: -18.47% | +2.0%Neutral MonthMar 2025: +1.97% | -15.8%Negative MonthApr 2025: -15.80% | +5.3%Positive MonthMay 2025: +5.33% | -10.7%Negative MonthJun 2025: -10.70% | -8.8%Negative MonthJul 2025: -8.75% | +46.2%Positive MonthAug 2025: +46.16% | -13.0%Negative MonthSep 2025: -12.97% | -4.3%Negative MonthOct 2025: -4.32% | +8.6%Positive MonthNov 2025: +8.63% | -3.3%Negative MonthDec 2025: -3.32% |
| 2024 | -13.7%Negative MonthJan 2024: -13.73% | -12.7%Negative MonthFeb 2024: -12.72% | -5.7%Negative MonthMar 2024: -5.71% | -6.1%Negative MonthApr 2024: -6.06% | +2.6%Positive MonthMay 2024: +2.62% | -5.5%Negative MonthJun 2024: -5.50% | +8.8%Positive MonthJul 2024: +8.80% | +12.0%Positive MonthAug 2024: +11.99% | -0.4%Neutral MonthSep 2024: -0.43% | +4.1%Positive MonthOct 2024: +4.12% | -10.6%Negative MonthNov 2024: -10.57% | -17.8%Negative MonthDec 2024: -17.84% |
| 2023 | +8.0%Positive MonthJan 2023: +7.99% | +5.3%Positive MonthFeb 2023: +5.29% | +17.7%Positive MonthMar 2023: +17.70% | -4.6%Negative MonthApr 2023: -4.61% | +24.0%Positive MonthMay 2023: +24.04% | +29.5%Positive MonthJun 2023: +29.52% | +5.6%Positive MonthJul 2023: +5.60% | -12.2%Negative MonthAug 2023: -12.16% | -13.7%Negative MonthSep 2023: -13.73% | -1.6%Neutral MonthOct 2023: -1.57% | +24.4%Positive MonthNov 2023: +24.41% | +9.8%Positive MonthDec 2023: +9.82% |
| 2022 | -0.9%Neutral MonthJan 2022: -0.86% | +20.0%Positive MonthFeb 2022: +20.01% | +29.6%Positive MonthMar 2022: +29.56% | -1.2%Neutral MonthApr 2022: -1.20% | +4.7%Positive MonthMay 2022: +4.71% | -6.3%Negative MonthJun 2022: -6.33% | +7.5%Positive MonthJul 2022: +7.47% | -20.8%Negative MonthAug 2022: -20.83% | -5.1%Negative MonthSep 2022: -5.07% | +10.0%Positive MonthOct 2022: +9.96% | -4.6%Negative MonthNov 2022: -4.56% | -5.0%Negative MonthDec 2022: -4.98% |
| 2021 | — | — | — | — | +8.7%Positive MonthMay 2021: +8.74% | +6.6%Positive MonthJun 2021: +6.55% | +3.9%Positive MonthJul 2021: +3.92% | -6.2%Negative MonthAug 2021: -6.16% | -3.3%Negative MonthSep 2021: -3.31% | -1.7%Neutral MonthOct 2021: -1.74% | +4.7%Positive MonthNov 2021: +4.71% | +19.1%Positive MonthDec 2021: +19.07% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
